[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349023-105":59,"doc-detail-349023-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","toward-the-simultaneous-detection-of-multiple-diseases-with-a-highly-cost-effective-cell-free-dna-methylome-test","Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test","","Plasma cell-free DNA (cfDNA) reflects DNA fragments shed from multiple organs and enables noninvasive diagnostics and prognostics. Current cfDNA methylation assays often target single clinical indications, while comprehensive cfDNA methylome profiling could support simultaneous disease detection using organ-specific methylation signatures. Deep sequencing remains too expensive for routine use. MethylScan addresses this by providing a highly cost-effective cfDNA methylome sequencing approach validated in 1,061 individuals across multiple clinical tasks.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/toward-the-simultaneous-detection-of-multiple-diseases-with-a-highly-cost-effective-cell-free-dna-methylome-test/349023/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/toward-the-simultaneous-detection-of-multiple-diseases-with-a-highly-cost-effective-cell-free-dna-methylome-test/349023.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the MethylScan approach address in cfDNA methylation testing?","Question",{"text":113,"@type":114},"It reduces the cost barrier of deep sequencing required for sensitive cfDNA methylome detection, enabling broader clinical use.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does MethylScan enable simultaneous detection of multiple diseases?",{"text":118,"@type":114},"It captures organ-specific methylation signatures across the cfDNA methylome rather than targeting a single panel of loci.",{"name":120,"@type":111,"acceptedAnswer":121},"What clinical applications were evaluated using MethylScan in the study cohort?",{"text":122,"@type":114},"Multicancer detection, liver cancer surveillance, liver disease classification, identification of organ abnormalities, and race/ancestry prediction from cfDNA.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349023,1790195194,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE  \nMEDICAL SCIENCES  \n OPEN ACCESS  \nToward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test  \nWeihua Zenga,1, Chun-Chi Liub,1 , Shuo Lia,1, Yonggang Zhoua,1, Mary L. Stackpoleb, Ying Xiaob, Ran Hua , Caitlin Tanga, Qiao Liuc , Wanwen Zengc, Angela Yehd, Andrew Melehye, Benjamin Trane , Zorawar Noord, Megumi Yokomizof, Dominic Amarae, Shreya Gumatee , Preeti Ahujaf, David Yuanze Lig, Junting Zhaoh, Inga Rosei, Cattlena Walkerj, Sadaf Malikj, Yazhen Zhua,k, Hsian-Rong Tsengk,l, Edward B. Garond,k, Samuel W. Frencha,k , Clara E. Magyara,k, Sarah M. Drya,k, Clara M. Lajoncherek,m, Daniel Geschwindm, Gina Choid, Sammy Saabd, Akshay Shettyd, Carrie R. Wongn , Kevin G. Kingf, David S. Luf, Steven S. Ramanf, Xiyan Xiango, Kirti Shettyp, Lopa Mishrao,q, Sanaz Memarzadehk,l,r,s,t,u, Yan Liuv, Frank Alberw,x, William Hsuf,y , Kostyantyn Krysand, Steven M. Dubinetta,d,k,l,u, Denise R. Aberlef,k, Vatche Agopiane,k , Steven-Huy B. Hand,k,  \nWing Hung Wongc,z, Xiaohui Nib,2, Wenyuan Lia,2, and Xianghong Jasmine Zhoua,k,x,2  Affiliations are included on p. 10.  \nEdited by Jens Nielsen, BioInnovation Institute, Hellerup, Denmark; received July 14, 2025; accepted January 25, 2026  \nPlasma cell-free DNA (cfDNA), originating from multiple organs, holds significant potential for noninvasive diagnostics and prognostics. Current cfDNA methylation assays primarily focus on single clinical indications by targeting specific genomic loci. In contrast, comprehensive profiling of cfDNA methylome can enable simultaneous detection of multiple diseases by capturing organ-specific methylation signatures, thereby offering a holistic view of health, when disease etiology is unclear or when conventional biochemical diagnostics are unavailable. However, deep sequencing required for sensitive detection of methylation abnormalities remains prohibitively expensive, limiting widespread clinical use. To overcome this barrier, we developed MethylScan, a highly cost-effective approach for cfDNA methylome sequencing. We demonstrated its broad clinical utility in a cohort of 1,061 individuals across diverse applications, including multicancer detection in general population, liver cancer surveillance in high-risk individuals, liver disease classification, identification of organ abnormalities, and race prediction from cfDNA. In multicancer detection (liver, lung, ovarian, and stomach cancers), MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3%(95% CI: 58.9 to 67.9%) at 98.0% specificity for all cancer stages. For early-stage cancers, the AUROC was 0.916 (95% CI: 0.890 to 0.940), with 55.3% sensitivity (95% CI: 49.1 to 62.1%) at the same specificity. In liver cancer surveillance, MethylScan achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.  \ncell-free DNA | DNA methylation | disease detection | cancer detection | liquid biopsy  \nWhen cells die, they do not simply vanish; they leave behind molecular traces, including cell-free DNA (cfDNA) in the blood stream. cfDNA is a mixture of DNA fragments released from various organs, offering valuable insights into the health of these organs. Among the features of cfDNA, methylation has demonstrated significant potential for noninvasive diagnostic and prognostic applications ( 1–4). Unlike an individual’s genome, which remains largely stable across tissues and over time (except for rare somatic mutations), the DNA methylome is tissue-specific (3, 5) and dynamically changes with the tissue’s disease status (6). Nearly all diseases can leave a signature in cfDNA methylationin two key ways: 1) Aberrant DNA methylation patte","cbCaisGcREm6MbDk","https://ap.wps.com/l/cbCaisGcREm6MbDk","pdf",2854760,"English","# Toward MethylScan for simultaneous disease detection\n## Rationale and limitations of current cfDNA methylation assays\n## MethylScan approach and validation across clinical applications","[{\"question\":\"What problem does the MethylScan approach address in cfDNA methylation testing?\",\"answer\":\"It reduces the cost barrier of deep sequencing required for sensitive cfDNA methylome detection, enabling broader clinical use.\"},{\"question\":\"How does MethylScan enable simultaneous detection of multiple diseases?\",\"answer\":\"It captures organ-specific methylation signatures across the cfDNA methylome rather than targeting a single panel of loci.\"},{\"question\":\"What clinical applications were evaluated using MethylScan in the study cohort?\",\"answer\":\"Multicancer detection, liver cancer surveillance, liver disease classification, identification of organ abnormalities, and race/ancestry prediction from cfDNA.\"}]","Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test | PDF",1790081239,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0eae6e641f76d3273019f19e9b4d589e.webp",983,1316,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9713e018b113a3262b6cf156a16c10dd.webp",982,1315,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d136490300365f588daa35c1444b4a77.webp",981,1313,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4166f8ada9412d8ca0610634916d9a7b.webp",980,1312]